Lysophosphatidylcholine increases apolipoprotein B secretion by enhancing lipid synthesis and decreasing its intracellular degradation in HepG2 cells.
Free fatty acids and lysophosphatidylcholine (lysoPC) are the major lipids bound to human plasma albumin. The effects of fatty acids on the hepatic production of Apolipoprotein B (apo B) have been studied but those of lysoPC have not. In HepG2 cells, lysoPC increased apo B secretion in different experiments by 50-120%, but did not affect the flotation properties of secreted lipoproteins. LysoPC affected neither the cellular protein levels nor apo A-I secretion suggesting that its effect was specific to apo B. Apo B secretion was maximum after incubating cells for 6 h with 0.2 mM lysoPC as equimolar fatty acid free bovine serum albumin (BSA) complexes. LysoPC was metabolized by cells and its fatty acids were used for the synthesis of phosphatidylcholine and triglycerides (TG). Experiments were performed to understand the mechanism of lysoPC action. LysoPC increased the incorporation of 3H-glycerol into newly synthesized cellular (3-fold) and secreted (4-fold) triglycerides, and increased the synthesis (40%) and secretion (4-fold) of phospholipids. LysoPC did not affect apo B synthesis, but inhibited the intracellular degradation of apo B and increased its secretion. Triacsin C (5 microM), an inhibitor of long chain acyl-CoA synthase, completely inhibited the induction of lipid synthesis and abolished the effect of lysoPC on apo B secretion. These studies indicated that lysoPC increased apo B secretion by inducing lipid synthesis; newly synthesized lipids probably protected apo B from intracellular degradation and enhanced secretion. These studies are consistent with the hypothesis that physiologic concentrations of lysoPC can be an important modulator for hepatic apo B secretion.
Zhou
Z
Z
Department of Pathology, The Allegheny University of the Health Sciences, MCP Hahnemann School of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA.
Luchoomun
J
J
Bakillah
A
A
Hussain
M M
MM
D016632:Apolipoprotein A-I / Q000378:metabolism; D001055:Apolipoproteins B / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D002499:Centrifugation, Density Gradient; D005227:Fatty Acids / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000096:biosynthesis; D008244:Lysophosphatidylcholines / Q000494:pharmacology*; D010713:Phosphatidylcholines / Q000096:biosynthesis; D010743:Phospholipids / Q000096:biosynthesis / Q000494:pharmacology; D014176:Protein Biosynthesis; D012710:Serum Albumin, Bovine / Q000378:metabolism; D014226:Triazenes / Q000494:pharmacology; D014280:Triglycerides / Q000096:biosynthesis / Q000378:metabolism; D014407:Tumor Cells, Cultured
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D005227:Fatty Acids; D008055:Lipids; D008244:Lysophosphatidylcholines; D010713:Phosphatidylcholines; D010743:Phospholipids; D014226:Triazenes; D014280:Triglycerides; D012710:Serum Albumin, Bovine; C034613:triacsin C; D005990:Glycerol